My PhD, under the supervision of Dr. Chalayer, focuses on alterations of haemostasis in patients with multiple myeloma (MM) and their treatments. I am investigating hypercoagulable changes in MM (elevated FVIII, increased thrombin generation in the presence of thrombomodulin, D-dimers…) with a phenotyping of coagulation in these patients. Additionally, I have attempted to characterize extracellular vesicles in the plasma of MM patients with physicochemical parameters, immunophenotyping, and functional assays (notably EVs bearing tissue factor or procoagulant phospholipids) to understand alterations in this pathology and interactions with treatments. We are working on the implementation of some of these candidate biomarkers to guide the use of thromboprophylaxis in MM patients.

Furthermore, the characterization of subpopulations of EVs allows us to gain knowledge on the expression of EV surface markers, especially for endothelial markers (in the context of immunomodulatory drugs or CAR T cells) and markers targeted by immunotherapy (antitumor treatment CD38, BCMA/CD269). I am also focusing on the expression of proteins (CD38, CD138, and CD269) on plasma cell EVs.

• Lessons, tutorials and practical work and in Licence Sciences pour la Santé (UEs Analyse cellulaire et instrumentations associées, Physiologie et métabolismes, Stratégie de prévention)
• Tutorials in Master 1 (Haematology and oncology section).
• Tutorial and practical work in Licence Biologie cellulaire et physiologie

• Orcid